respiratory
Cystic fibrosis

Kalydeco listed on PBS for children aged 12-24 months


Respiratory medicine specialists have welcome the announcement that ivacaftor (Kalydeco) will be subsidised on the PBS for children aged 12-24 months with cystic fibrosis (CF) from 1 August. The drug is currently subsidised for about 280 patients over two years of age  who have a G551D mutation or other class III gating mutations in the ...

Already a member?

Enter your email to keep reading.


OR